此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Anesthesia Type and HoLEP Outcomes: A Multi-Center Study

2026年5月9日 更新者:Murat Gulsen、Ondokuz Mayıs University

Does Anesthesia Type Affect HoLEP Outcomes? A Multi-Center, Real-World Comparative Study

  1. What is this study about, and why is it required?

    The goal of this observational study is to learn if anesthesia type (e.g., general anesthesia, spinal anesthesia) affects the safety and efficiency of HoLEP surgery. The main question it aims to answer is:

    - Is a particular type of anesthesia related to less or more bleeding during the surgery?

  2. What will be assessed to answer the main question of this study? (Outcome measure(s))

    2.1. Primary outcome measure of this study is:

    - Change in the hemoglobin level perioperatively.

    2.2. Secondary outcome measures are:

    • Requirement for the usage of any vasoactive medication due to low blood pressure
    • Time passed until discharge.
    • Time passed until the removal of the bladder drainage catheter.
    • Ratio of the unwanted events that require additional intervention other than medication, fluids, or blood transfusions (Complications, Clavien-Dindo Grade III or higher).
    • International symptom questionnaire score 3 months after surgery.
    • Quality of life (QoL) score 3 months after surgery.
    • Peak urinary current velocity (Qmax) and post-void residual volume measurement 3 months after surgery.
  3. Can anyone participate in this study?

Voluntary participants should meet the following criteria:

  • Being older than 18 years old.
  • Having bothersome lower urinary tract symptoms due to prostatic enlargement requiring surgical treatment.
  • Having no untreated or uncontrolled systemic disease, which refers to having an ASA (American Society of Anesthesiologists Physical Status Classification System) score III at most.

研究概览

详细说明

Benign prostatic obstruction (BPO) is the leading cause of lower urinary tract symptoms (LUTS) among men older than 40 years.

Surgery is recommended under circumstances such as:

  • Bothersome LUTS resistant to medical treatment.
  • Acute kidney injury, bladder stone(s), resistant hematuria and urinary retention.
  • Preference of the patient.

Various surgical methods exist to treat BPO, but the most appropriate choice depends on the operator and the patient.

HoLEP is an abbreviation for holmium laser enucleation of prostate, which is one of the endoscopic laser enucleation techniques.

Both spinal and general anesthesia are applicable for HoLEP surgery. The type of anesthesia is determined by the anesthesiologist, independently of the operator's preference, taking into account several factors related to the patient, such as safety and comfort.

Controlled bleeding is one of the expected outcomes in HoLEP, and several factors determine the amount of bleeding. For HoLEP, the type of anesthesia may be one of them, as other studies have claimed. This multicenter, prospective observational study may further reveal the impact of anesthesia type on bleeding.

The amount of bleeding could be "less or more", determined according to the content below:

  • Amount of hemoglobin and hematocrit decreased, measured by laboratory examinations, preoperatively, during, and on the day after the surgery.
  • Vital changes such as hypotension, tachycardia, that require blood transfusion due to "more" bleeding during either the surgery or hospital stay after surgery.
  • Usually, a shorter duration of bladder irrigation to clean blood in the urine during hospital stay after the surgery is required for "less" bleeding.

Participants who are eligible and willing to provide informed consent will undergo HoLEP. Preoperative, perioperative, and postoperative data will be collected without disclosing the participant or any personal data relating to the participant.

Participants will be grouped into two groups based on anesthesia type: general or spinal.

To answer the main question of this study, a power analysis was conducted, concluding that at least 320 participants are required (intention-to-treat population).

All collected data will be recorded and analyzed according to the proper statistical methods. Results will be reported.

研究类型

观察性的

注册 (估计的)

320

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Murat Gulsen, Assistant Professor
  • 电话号码:+905062357421
  • 邮箱:mglotr@gmail.com

学习地点

      • Samsun、土耳其(türkiye)
        • Ondokuz Mayis University, Faculty of Medicine, Department of Urology
        • 接触:
          • Murat Gulsen, Assistant Professor
          • 电话号码:+905062357421
          • 邮箱:mglotr@gmail.com

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

概率样本

研究人群

Male patients undergoing HoLEP for BPO.

描述

Inclusion Criteria:

  • 18 years or older men who have BPO requiring surgical treatment.
  • Participants who can give written informed consent.
  • Having no more than 3 points for the American Society of Anesthesiologists (ASA) physical status classification scale (ASA 1 to 3).

Exclusion Criteria:

  • Absolute contraindication for spinal or general anesthesia
  • History of previous surgery for prostate (e.g., surgery for prostate cancer, surgery for benign prostate obstruction)
  • Uncorrected bleeding disorder (INR > 1.5)
  • Participants who are not willing to give informed consent.
  • Participants who have a proven urinary tract infection at the time of the surgery.
  • Participants who are not able to be contacted for regular follow-ups.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
General Anesthesia
Participants undergoing HoLEP under general anesthesia (intubation or laryngeal mask airway)
Spinal Anesthesia
Participants undergoing HoLEP under spinal anesthesia

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Hemoglobin change
大体时间:First day after HoLEP is performed.
Difference between preoperative and postoperative hemoglobin levels (g/dL)
First day after HoLEP is performed.

次要结果测量

结果测量
措施说明
大体时间
International Prostate Symptom with quality of life score (IPSS-QoL) at 3 months after surgery
大体时间:At 3 months after HoLEP

The severity of lower urinary tract symptoms and their impact on quality of life should be assessed using a validated questionnaire.

  • 0 to 35 points for IPSS
  • 0 to 6 points for QoL Scale variable.
At 3 months after HoLEP
Duration of hospitalization
大体时间:Postoperative second to seventh days after HoLEP.
Day(s) passed until discharge after HoLEP.
Postoperative second to seventh days after HoLEP.
Duration of catheterization
大体时间:From the time of HoLEP until the removal of the catheter.
Day(s) passed until the removal of the bladder drainage catheter after HoLEP.
From the time of HoLEP until the removal of the catheter.
Ratio of high grade complications
大体时间:From the time of HoLEP to 30 days after HoLEP.
Complications will be classified according to the Clavien-Dindo classification. Clavien-Dindo Grade III or higher is considered a high-grade complication.
From the time of HoLEP to 30 days after HoLEP.
Peak Urinary Flow (Qmax)
大体时间:At 3 months after HoLEP.
Peak urinary flow (mL/sec), at 3 months after HoLEP.
At 3 months after HoLEP.
Post-void residual (PVR)
大体时间:At 3 months after HoLEP
Post-void residual (PVR) volume (mL) measurement at 3 months after HoLEP
At 3 months after HoLEP
Enucleation Efficiency
大体时间:From the start of HoLEP to the end of HoLEP (Operative time).
Weight of the enucleated adenoma per operative minute (grams/min).
From the start of HoLEP to the end of HoLEP (Operative time).
Ratio of intraoperative vasoactive medication requirement
大体时间:During the anesthesia for HoLEP
Number of participants who required vasoactive medication during anesthesia for HoLEP due to low blood pressure, as a percentage of the total number of participants.
During the anesthesia for HoLEP

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Murat Gulsen、Ondokuz Mayıs University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年4月23日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2026年5月5日

首先提交符合 QC 标准的

2026年5月9日

首次发布 (实际的)

2026年5月13日

研究记录更新

最后更新发布 (实际的)

2026年5月13日

上次提交的符合 QC 标准的更新

2026年5月9日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data (IPD) will not be shared due to privacy concerns and data protection regulations, including the Turkish Personal Data Protection Law (KVKK).

Only aggregated, de-identified results will be reported in publications and presentations.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅